Fig. 3.
Kaplan–Meier curves of progression-free survival (top) and overall survival (OS, bottom) in the elderly (≥70 years of age) patients treated on a randomized phase III clinical trial comparing nab-paclitaxel/carboplatin (nab-PC) versus solvent-based paclitaxel/carboplatin (sb-PC) in patients with newly diagnosed advanced non-small cell lung cancer. Reprinted with permission from Annals of Oncology 24: 314–321, 2013.